- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
April 4th, 2007
n health sector news, Australian bio-nanotech Psivida Ltd. surged 80 cents, or 39.2 percent, to $2.84 in the early session after signing an exclusive research and license agreement for its drug delivery technology with Pfizer Inc.
Under the agreement, which centers on ophthalmic, or eye-care products, Psivida will receive up to $155 million in development and sales-related milestone payments, and royalties on future products.
|Related News Press|
PEN Inc. Announces 1-for-180 Reverse Stock Split January 27th, 2016
Interviews/Book Reviews/Essays/Reports/Podcasts/Journals/White papers
Scientists take nanoparticle snapshots February 10th, 2016
Chemical cages: New technique advances synthetic biology February 10th, 2016